ECM
ESPR icon

Exchange Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Exchange Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-550
Closed -$22K – 164
2014
Q4 		$22K Hold
550
– – 0.01% 135
2014
Q3 		$13K Buy
+550
New +$8.74K 0.01% 153

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Polar Capital
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Exchange Capital Management's ESPR Position: Q1 2015 in Review

Exchange Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2015, closing a stake of 550 shares — an estimated $22K sold.

Exchange Capital Management first reported a position in ESPR in Q3 2014 and held it in 2 quarters. The position peaked at $22K in Q4 2014. 141 funds tracked by Wall St. Rank hold ESPR as of Q1 2015.

  • Exchange Capital Management reported no remaining Esperion Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Exchange Capital Management sold 550 Esperion Therapeutics shares in Q1 2015, an estimated $22K.
  • Exchange Capital Management first reported a position in Esperion Therapeutics in Q3 2014 and held it in 2 quarters.
  • Exchange Capital Management's Esperion Therapeutics position peaked at $22K in Q4 2014.
  • 141 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2015.

Based on Exchange Capital Management's 13F filing for Q1 2015, filed 17 Apr 2015.